August 29, 2016Celgene backs next-gen oncolytic virus startup in $57M Series ALearn More
“Newly unveiled Oncorus has raised a $57 million Series A to back its efforts to use next-gen oncolytic viruses to treat aggressive cancers including a type of brain cancer, glioblastoma multiforme (GBM). Active strategic investor Celgene ($CELG) participated in the financing, which was led by MPM Capital.” Read the article from FierceBiotech
August 29, 2016A Q&A with CEO of Oncorus that just raised $57M to battle cancerLearn More
“The Cambridge, Massachusetts, startup launched on Tuesday announcing that it has raised $57 million in a Series A funding round. Oncorus aims to develop a next-generation immunotherapy platform of oncolytic viruses to treat various kinds of tumors, including highly malignant and aggressive cancers such as glioblastoma multiforme.” Read the article from MedCity News.
July 19, 2016Oncorus, Inc. Launches with $57 Million Series A FinancingLearn More
To view a full PDF, click here.
Media Inquiries: email@example.com